Rio Piedras, Puerto Rico Clinical Trials

A listing of Rio Piedras, Puerto Rico clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 83 clinical trials
featured
Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

www.MyelofibrosisResearch.com Myelofibrosis (MF) is a bone marrow illness that affects blood-forming tissues in the body. MF disturbs the body's normal production of blood cells, causing extensive scarring in the bone marrow. This leads to severe anemia, weakness, fatigue, and an enlarged spleen. The purpose of this study is to assess …

Hospital del Centro Comprensivo de Cancer de la UPR /ID# 223281
 (1.8 away) Contact site
  • 164 views
  • 29 Apr, 2021
  • +224 other locations
featured
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

This Phase 3 study will evaluate the efficacy of the investigational agent MRTX849 versus docetaxel in patients who have been previously treated for metastatic NSCLC with a KRAS G12C mutation.

lung metastases
recurrent non-small cell lung cancer
refractory non-small cell lung cancer
advanced lung cancer
lung cancer
Mirati Research Site
 (2.0 away) Contact site
  • 0 views
  • 08 Jun, 2021
  • +33 other locations
featured
A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy (KRYSTAL-10)

Study 849-010 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Fundación de Investigación de Diego (FDI) Clinical Research
 (1.4 away) Contact site
  • 0 views
  • 16 Jun, 2021
  • +17 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

This study will evaluate the efficacy and safety of pembrolizumab (MK-3475) with lenvatinib (E7080/MK-7902) vs. docetaxel in participants with metastatic non-small cell lung cancer (NSCLC) and progressive disease (PD) after platinum doublet chemotherapy and treatment with one prior anti-PD-1/PD-L1 monoclonal antibody (mAb). The primary hypotheses of this study are that …

metastasis
docetaxel
pembrolizumab
cancer
mk-3475
Puerto Rico Medical Research Center LLC ( Site 2101)
 (2.6 away) Contact site
  • 122 views
  • 12 Jun, 2021
  • +147 other locations
Tislelizumab in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Carcinoma

This is a randomized (1:1), double-blind, placebo-controlled, Phase 3 study designed to compare the efficacy and safety of tislelizumab or placebo plus chemotherapy as first-line (1L) therapy for locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Pan American Oncology Trials, LLC
 (6.8 away) Contact site
  • 38 views
  • 25 Jan, 2021
  • +193 other locations
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine

The main purpose of this study is to evaulate the efficacy and safety of galcanezumab in participants 6 to 17 years of age for the preventive treatment of episodic migraine. The primary objective is to demonstrate the superiority of galcanezumab versus placebo in the reduction of monthly migraine headache days …

Barbara Diaz Hernandez
 (1.8 away) Contact site
  • 43 views
  • 16 Jun, 2021
  • +91 other locations
A Study of Heterologous Vaccine Regimen of Adenovirus Serotype 26 Mosaic4 Human Immunodeficiency Virus(Ad26.Mos4.HIV) Adjuvanted Clade C gp140 and Mosaic gp140 to Prevent HIV-1 Infection Among Cis-gender Men and Transgender Individuals Who Have Sex With Cis-gender Men and/or Transgender Individuals

The purpose of this study is to evaluate the vaccine efficacy (VE) of a heterologous vaccine regimen utilizing Ad26.Mos4.HIV and aluminum phosphate-adjuvanted Clade C gp140 and Mosaic gp140 for the prevention of HIV-1 infection in HIV-1 seronegative cis-gender men and transgender individuals having sex with cis-gender men and/or transgender individuals.

Clinical Research Puerto Rico Inc
 (4.1 away) Contact site
  • 74 views
  • 24 May, 2021
  • +78 other locations
Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab with SoC SBRT versus placebo with SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3N0M0) NSCLC.

lung carcinoma
stereotactic body radiation therapy
durvalumab
Research Site
 (1.8 away) Contact site
  • 68 views
  • 28 Apr, 2021
  • +226 other locations
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168)

Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary Objective: To assess efficacy of SAR442168 compared to teriflunomide (Aubagio) on disability progression, MRI lesions, cognitive performance …

teriflunomide
pregnancy test urine
brain lesion
hmr1726
contraceptive use
Investigational Site Number 8400015
 (4.9 away) Contact site
  • 10 views
  • 17 Jun, 2021
  • +121 other locations
Study of Evobrutinib in Participants With RMS (evolutionRMS 2)

The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS).

teriflunomide
evobrutinib
aubagio
Research Site 791
 (5.0 away) Contact site
  • 0 views
  • 19 Jun, 2021
  • +220 other locations